Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
The Pharma Data
MARCH 8, 2021
In addition to the ongoing clinical studies, Merck has conducted a comprehensive nonclinical program to characterize the safety profile of molnupiravir. This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo.
69 
Let's personalize your content